UW Health and UnityPoint Health–Meriter have received a limited supply (116 doses) of bamlanivimab, an investigational therapy for the treatment of mild-to-moderate COVID-19 in adult and pediatric patients.
Office of Strategic Communication
UW Health and UnityPoint Health–Meriter have received a limited supply (116 doses) of bamlanivimab, an investigational therapy for the treatment of mild-to-moderate COVID-19 in adult and pediatric patients.